ID | 1120 |
Name of the vaccine | PedaTyph |
Microbe | Bacteria |
Disease name | Typhoid |
Name of bacteria | Salmonella typhi |
Type of vaccine | Conjugate |
Nucleic acid content | DNA |
Age | From 3 months |
Description of the vaccine | Purified Vi capsular polysaccharide of Salmonella typhi (Strain Ty2) conjugated with Tetanus toxoid protein. |
Name of the manufacturer | BIO-MED Private Limited |
Name of the manufacturing country | India |
Year of manufacture | 2008 |
Clinical Phase status | Approved |
Bacterial strain | Gram negative bacteria. |
Efficacy | Efficacy has been found to be 100% over a follow up period of 1 year. |
Vaccine formulation | Turbid solution |
Dosage | Single dose followed by booster after 2.5-3 years of primary vaccination. |
Mechanism of action | T cell dependent response. |
Route of administration | Intramuscular |
Indications | Active immunization against Salmonella typhi in infants, children and adults. |
Export | Marketed by: BIO-MED Private Limited, India |
Approval | Licensed in India and not WHO prequalified |
Adjuvant | NA |
Repurposing | NA |
Side effects of vaccine | Pain, induration, erythema, purities at the injection site. |
Post vaccination | NA |
Dose type | Single dose |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | http://www.biomed.co.in/peda-typh/ |
Other name | NA |
Additional Links | https://www.jcdr.net/article_fulltext.asp?id=5903
|